USPTO serial 88308511
PAIGE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 24, 2020
- Examiner
- MORRIS, KRISTINA KLOIBER
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with PAIGE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
New York, NY, US
New York, NY, US
New York, NY, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark Leonardo
Mark Leonardo NUTTER, MCCLENNEN & FISH, LLP155 SEAPORT BOULEVARDSEAPORT WESTBOSTON, MA 02210Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Software as a service (SaaS) services featuring software for artificial intelligence, machine learning, deep learning, statistical learning, data mining, and contextual prediction; software as a service (SaaS) services featuring software for use in disease pathology, namely, software that reads digital slides and provides diagnoses; software as a service (SaaS) services featuring software for use in diagnosis of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in evaluation of prognosis relating to diseases, states, or conditions; software as a service (SaaS) services featuring software for use in monitoring of diseases, states, or conditions; software as a service (SaaS) services featuring software for use to detect or identify predispositions to diseases, states, or conditions; software as a service (SaaS) services featuring software to detect the recurrence of diseases, states, or conditions; software as a service (SaaS) services featuring software to detect, monitor, or evaluate patients' responses to treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in clinical management of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in the selection of treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in prevention of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in palliation or treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in research or development in the field of life sciences; software as a service (SaaS) services featuring software for use in research or development in the field of medicine; software as a service (SaaS) services featuring software for use in research or development in the field of healthcare; software as a service (SaaS) services featuring software for use in research or development in the field of cancer; software as a service (SaaS) services featuring software for use in research or development in the field of oncology; software as a service (SaaS) services featuring software for use in research or development in the field of pathology; design and development of AI-powered computer software that analyzes clinical pathology slides and diagnoses diseases; medical research; scientific research and development services in the field of pathology; research and development services in the field of medicine; research and development services in the field of cancer; research and development services in the field of healthcare; research and development services in the field of life sciences; research and development services in the field of oncology; medical and scientific research services in the field of pathology; medical and scientific research services in the field of cancer; medical and scientific research services in the field of healthcare; medical and scientific research services in the field of life sciences; medical and scientific research services in the field of oncology; research and development of technology in the field of pathology; research and development of technology in the field of medicine; research and development of technology in the field of cancer; research and development of technology in the field of healthcare; research and development of technology in the field of life sciences; research and development of technology in the field of oncology; providing medical research and scientific research information via the internet; electronic scanning of clinical pathology slides; software as a service services (SaaS) featuring software for use in the analysis of clinical pathology slides; medical and scientific testing services for research purposes | ACTIVE | Feb 21, 2019 |
| 044 | Medical services; cancer therapy services; medical testing, namely, the review and analysis of patients' clinical slides to identify additional recommended medical testing; medical testing for the diagnosis of diseases, states, or conditions; medical testing for evaluation of prognosis relating to diseases, states, or conditions; medical testing for the monitoring of diseases, states, or conditions; medical testing to detect or identify predispositions to diseases, states, or conditions; medical testing to detect or determine the recurrence of diseases, states, or conditions; medical testing to detect, monitor, or evaluate responses to treatment of diseases, states, or conditions; medical testing to evaluate clinical management of diseases, states, or conditions; medical testing for selection of treatment for diseases, states, or conditions; medical testing to evaluate or facilitate prevention of diseases, states, or conditions; medical testing to select, facilitate, monitor, or evaluate palliation or treatment of diseases, states or conditions; medical testing in the field of cancer; medical testing in the field of oncology; medical diagnostic testing, monitoring, or reporting services; medical analysis or advisory services in the field of cancer; medical analysis or advisory services in the field of oncology; medical analysis or advisory services for medical treatment; medical analysis or advisory services for the diagnosis of diseases, states, or conditions; medical analysis or advisory services for the evaluation of prognosis relating to diseases, states, or conditions; medical analysis or advisory services relating to monitoring diseases, states, or conditions; medical analysis or advisory services relating to the detection or identification of predispositions to diseases, states, or conditions; medical analysis or advisory services relating to the detection or determination of the recurrence of diseases, states, or conditions; medical analysis or advisory services relating to the detection, monitoring, or evaluation of responses to treatment of diseases, states, or conditions; medical analysis or advisory services relating to the clinical management of diseases, states, or conditions; medical analysis or advisory services relating to the selection of treatment for diseases, states, or conditions; medical analysis or advisory services relating to the prevention of diseases, states, or conditions; medical analysis or advisory services relating to the palliation or treatment of diseases, states or conditions; qualitative image analysis in the field of digital pathology for medical purposes; quantitative image analysis in the field of digital pathology for medical purposes; providing non-research related medical information via the internet; medical analysis services for the diagnosis of cancer by reviewing pathological samples on slides | ACTIVE | Feb 21, 2019 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 17, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 17, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 17, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 4, 2026 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Mar 4, 2026 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Mar 4, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 1, 2025 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Nov 24, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jan 29, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 29, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 29, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 29, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 29, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 24, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 22, 2020 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Oct 21, 2020 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Oct 21, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 21, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 13, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 13, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 13, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 13, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 13, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 13, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 11, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 11, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 11, 2020 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2020 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Aug 12, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 31, 2020 | IUAF | USE AMENDMENT FILED | — |
| Jul 31, 2020 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jul 8, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 8, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 8, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 8, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 8, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 24, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 22, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 22, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 22, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 22, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 11, 2019 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Aug 14, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 14, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 31, 2019 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jul 2, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 2, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 12, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 29, 2019 | ALIE | ASSIGNED TO LIE | — |
| May 15, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 15, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 15, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 15, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 15, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 1, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 12, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 23, 2019 | NWAP | NEW APPLICATION ENTERED | — |